A bicentric retrospective study of the correlation of EAU BCR risk groups with F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence.
Fiche publication
Date publication
mai 2024
Journal
Scientific reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr IMPERIALE Alessio, Dr SOMME François
Tous les auteurs :
Poterszman N, Merlin C, Margail C, Ouvrard E, Imperiale A, Somme F
Lien Pubmed
Résumé
The European Association of Urology (EAU) has proposed a risk stratification for patients harboring biochemical recurrence (BCR) after radical prostatectomy: ISUP < 4 and PSA doubling time (PSAdt) > 12 months for low risk, and ISUP ≥ 4 or PSAdt ≤ 12 months for high risk. This dual-center retrospective study aims to investigate the correlation between the EAU risk stratification for BCR following radical prostatectomy and the detection rate of lesions using F-PSMA-1007 PET/CT. Among the 71 included patients (58 high-risk, 13 low-risk), with a median PSA level of 1.43 ng/ml, PET/CT demonstrated a significantly higher positivity in the high-risk group compared to the low-risk group (72.4% vs. 38.0%, p = 0.026). Analysis of recurrence sites revealed a similar proportion of pelvic-confined disease in both groups (24.1% vs. 23.1%, p = 0.935), but a significantly higher incidence of metastatic disease in the high-risk group (51.7% vs. 15.4%, p = 0.017), with detailed findings indicating an increased prevalence of bone metastases in the high-risk BCR group (37.8% vs. 7.7%, p = 0.048). Therefore, PSMA PET/CT offers valuable insights for treatment decisions, aligning with the evolving landscape of prostate cancer management.
Mots clés
Humans, Male, Positron Emission Tomography Computed Tomography, methods, Prostatic Neoplasms, diagnostic imaging, Retrospective Studies, Aged, Middle Aged, Neoplasm Recurrence, Local, diagnostic imaging, Prostatectomy, Prostate-Specific Antigen, blood, Oligopeptides, chemistry, Niacinamide, analogs & derivatives
Référence
Sci Rep. 2024 05 13;14(1):10908